Brief: RIBOMIC Inc Provides Update On RBM-007 Program
23/03/2022 13:30
March 23 (Reuters) - Ribomic Inc 4591.T :
* RIBOMIC INC. PROVIDES UPDATE ON RBM-007 PROGRAM IN WET
AGE-RELATED MACULAR DEGENERATION
* RIBOMIC INC - EARLY SIGNS OF EFFICACY IN TEMPURA STUDY
PROVIDE
INITIAL SUPPORT OF CLINICAL BENEFIT IN TREATMENT-NAÏVE WAMD
* RIBOMIC INC - NEW DATA SUGGESTS RBM-007 COULD BE MORE
EFFECTIVE
IN TREATMENT-NAÏVE VERSUS PREVIOUSLY TREATED WAMD
Source text for Eikon: ID:nBw9S4PGwa
Further company coverage: 4591.T
((Reuters.Briefs@thomsonreuters.com;))